PTC Inc. logo

PTC Inc. (PTC)

Market Open
21 Jul, 16:45
NASDAQ (NGS) NASDAQ (NGS)
$
122. 44
-2.39
-1.9146%
$
14.15B Market Cap
83.45 P/E Ratio
- Div Yield
377,548 Volume
4.29 Eps
$ 124.83
Previous Close
Add Transaction
Day Range
122.01 125.63
Year Range
108.5 219.69
Want to track PTC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
PTC Launches Codebeamer 3.0 to Boost Speed, Quality & Sustainability

PTC Launches Codebeamer 3.0 to Boost Speed, Quality & Sustainability

PTC launches Codebeamer 3.0 to speed up product development, boost sustainability and ensure quality and compliance with full traceability and smarter tools.

Zacks | 1 year ago
PTC Therapeutics says European Commission will remove muscle disorder drug

PTC Therapeutics says European Commission will remove muscle disorder drug

PTC Therapeutics said on Friday the European Commission will remove its inherited progressive muscle-wasting disorder from the region after an advisory panel reaffirmed a negative opinion of the drug in January.

Reuters | 1 year ago
PTC's Premium Valuation Justified By Strong Outlook, Buy On Dips

PTC's Premium Valuation Justified By Strong Outlook, Buy On Dips

PTC basically offers end-to-end software solutions for managing the product lifecycle across diverse industries. Their flagship platforms are Windchill, Codebeamer, ServiceMax, and Creo, which overall help with operational efficiency and quality improvements. PTC is also quickly transitioning toward cloud-native SaaS tools. Good examples of this are their Onshape and Arena new offerings.

Seekingalpha | 1 year ago
PTC to Showcase Windchill AI at Hannover Messe 2025: Stock to Gain?

PTC to Showcase Windchill AI at Hannover Messe 2025: Stock to Gain?

PTC will unveil Windchill AI, Codebeamer AI and ServiceMax AI at Hannover Messe 2025, promising innovation and fostering digital transformation.

Zacks | 1 year ago
PTC Therapeutics: Upside In Rare Disease Innovation

PTC Therapeutics: Upside In Rare Disease Innovation

PTC Therapeutics is poised for a potential turnaround with key FDA reviews in 2025 for vatiquinone and sepiapterin, despite past revenue declines. The company maintains a strong cash position of over $2 billion, providing a buffer as it awaits regulatory approvals to boost revenue. PTC's diversified pipeline, including vatiquinone for Friedreich's ataxia, could significantly enhance revenue if approved, targeting a $2.8 billion market.

Seekingalpha | 1 year ago
Why Is PTC Inc. (PTC) Down 6.4% Since Last Earnings Report?

Why Is PTC Inc. (PTC) Down 6.4% Since Last Earnings Report?

PTC Inc. (PTC) reported earnings 30 days ago. What's next for the stock?

Zacks | 1 year ago
Looking for Sneaky Growth? These 2 Stocks Are Low-Key Buys for 2025.

Looking for Sneaky Growth? These 2 Stocks Are Low-Key Buys for 2025.

Sometimes, the headline numbers don't tell the whole story. That's definitely the case with industrial software company PTC (PTC 0.05%) and workflow technology company Trimble (TRMB 1.11%).

Fool | 1 year ago
Here's Why PTC Stock Declined This Week (and Why It Looks Like a Good Value Now)

Here's Why PTC Stock Declined This Week (and Why It Looks Like a Good Value Now)

Shares in industrial software company PTC (PTC -9.84%) were lower by 8.8% in the week to Thursday afternoon. The move comes after a poorly received first-quarter 2025 earnings released on Wednesday.

Fool | 1 year ago
PTC's Q1 Earnings & Revenues Top Estimates, Up Y/Y on Market Strength

PTC's Q1 Earnings & Revenues Top Estimates, Up Y/Y on Market Strength

PTC's Q1 performance is driven by strength in its subscription-based business model and innovative product portfolio against a volatile sales backdrop.

Zacks | 1 year ago
PTC Inc. (PTC) Q1 2025 Earnings Call Transcript

PTC Inc. (PTC) Q1 2025 Earnings Call Transcript

PTC Inc. (NASDAQ:PTC ) Q1 2025 Earnings Conference Call February 5, 2025 5:00 PM ET Company Participants Matt Shimao - Head of Investor Relations Neil Barua - President and Chief Executive Officer Kristian Talvitie - Chief Financial Officer Conference Call Participants Jay Vleeschhouwer - Griffin Securities, Inc. Jason Celino - KeyBanc Capital Markets Inc. Ken Wong - Oppenheimer & Co. Inc. Siti Panigrahi - Mizuho Securities Co., Ltd. Stephen Tusa - JPMorgan Chase & Co. Arsenije Matovic - Wolfe Research, LLC Nay Soe Naing - Berenberg Saket Kalia - Barclays Operator Good afternoon, ladies and gentlemen.

Seekingalpha | 1 year ago
PTC Inc. (PTC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

PTC Inc. (PTC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for PTC Inc. (PTC) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks | 1 year ago
PTC Inc. (PTC) Tops Q1 Earnings and Revenue Estimates

PTC Inc. (PTC) Tops Q1 Earnings and Revenue Estimates

PTC Inc. (PTC) came out with quarterly earnings of $1.10 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $1.11 per share a year ago.

Zacks | 1 year ago
Loading...
Load More